Effect of Carbon Support, Capping Agent Amount, and Pd NPs Size for Bio-Adipic Acid Production from Muconic Acid and Sodium Muconate

The effect of support, stabilizing agent, and Pd nanoparticles (NPs) size was studied for sodium muconate and t,t-muconic acid hydrogenation to bio-adipic acid. Three different activated carbons (AC) were used (Norit, KB, and G60) and carbon morphology did not affect the substrate conversion, but it greatly influenced the adipic acid yield. 1% Pd/KB Darco catalyst, which has the highest surface area and Pd surface exposure, and the smallest NPs size displayed the highest activity. Furthermore, the effect of the amount of the protective agent was studied varying metal/protective agent weight ratios in the range of 1/0.00-1/1.20, using KB as the chosen support. For sodium muconate reduction 1% Pd/KB_1.2 catalyst gave the best results in terms of activity (0.73 s-1), conversion, and adipic acid yield (94.8%), while for t,t-muconic acid hydrogenation the best activity result (0.85 s-1) was obtained with 1% Pd/KB_0.0 catalyst. Correlating the results obtained from XPS and TEM analyses with catalytic results, we found that the amount of PVA (polyvinyl alcohol) influences mean Pd NPs size, Pd(0)/Pd(II) ratio, and Pd surface exposure. Pd(0)/Pd(II) ratio and Pd NPs size affected adipic acid yield and activity during sodium muconate hydrogenation, respectively, while adipic acid yield was related by exposed Pd amount during t,t-muconic acid hydrogenation. The synthesized catalysts showed higher activity than commercial 5% Pd/AC

Onset and evolution of dysphagia in Huntington’s Disease

Background Huntington's disease (HD) is a neurodegenerative disorder characterized by motor disturbances, cognitive decline and behaviour changes. Dysphagia is a well-recognized feature in advanced HD stage that leads to malnutrition and aspiration pneumonia, the latter representing the first causes of death in HD. However, no data are available about the onset of dysphagia during the disease course and the correlation between dysphagia severity and disease progression. Aim The aim of the study was to characterize dysphagia in patients with HD from early to advanced stages of the disease. Methods Dysphagia was investigated in 43 patients with HD by fiberoptic endoscopic examination of swallowing (FEES). FEES recordings were de-identified and assessed by a blinded judge. Dysphagia Outcome and Severity Scale (DOSS), Penetration-Aspiration Scale (PAS), and Yale Pharyngeal Residue Severity Rating Scale (YALE) were used to rate dysphagia severity, swallowing safety, and swallowing efficacy, respectively. For disease severity, all patients were assessed with the Unified Huntington's Disease Rating Scale (UHDRS) and were classi\ufb01ed as early-stage, moderate-stage or advanced stage HD based on Shoulson-Fahn stages. Results FEES was well tolerated in all the subjects. Data showed that 30% of early-stage patients with HD already exhibit dysphagia (DOSS 645). Prevalence of dysphagia noticeably increased to 90% in the moderate stage of the disease, while reached 100% in the advanced stage. PAS scores progressively worsened with the disease stage. On the contrary, YALE scores remained stable in the various stages of disease and showed a greater amount of residue in the valleculae compared to pyriform sinus. A Total Motor Score of the UHDRS >37 correctly identified patients with dysphagia with 82% sensitivity and 73% specificity. Conclusion This study provides a better understanding of dysphagia onset and development in HD and may guide the definition of clinical care standard for dysphagia recognition and management, aimed at reducing nutritional and pulmonary complications

Current exposure of Italian women of reproductive age to PFOS and PFOA: a human biomonitoring study

Perfluorooctane sulfonate (PFOS) and perfluorooctanoic acid (PFOA) concentrations were determined in serum samples collected in 2011-2012 from 549 nulliparous Italian women of reproductive age who resided in six different Italian Regions. Assessment of exposure to perfluorinated compounds was part of a large human biomonitoring study (Project Life Plus "Womenbiopop") that aimed at examining the exposure of women of reproductive age to priority organic pollutants. The median concentrations of PFOS and PFOA were 2.43, and 1.55ngg-1, respectively. Significant differences in the concentrations of both compounds were observed among the six Regions. Women from central Italy had the highest levels of both compounds, followed by women from northern Italy, and southern Italy. No differences in the PFOS concentrations were found between women from urban/industrial areas and women from rural areas, whereas the levels of PFOA were significantly higher in women residing in urban/industrial areas than in women residing in rural areas. Taken together, the observed concentrations confirm that the overall exposure of the Italian population is among the lowest observed in industrialized countries. A downward temporal trend in exposure was observed for both compounds when comparing the results from the present study with those assessed in a study conducted in 2008

Fluvastatin synergistically improves the antiproliferative effect of everolimus on rat smooth muscle cells by altering p27Kip1/cyclin E expression

Multiple intracellular signaling pathways stimulate quiescent smooth muscle cells (SMCs) to exit from G(0) and re-enter the cell cycle. Thus, a combination of two drugs with different mechanisms of action may represent a suitable approach to control SMC proliferation, a prominent feature of in-stent restenosis. In the present study, we investigated the effect of everolimus, a mammalian target of rapamycin inhibitor, in combination with fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on proliferation of rat SMCs. The antiproliferative action of everolimus was amplified by 2.5-fold by the addition of subliminal concentrations of fluvastatin (5 x 10(-7) M), lowering the IC(50) value from 2.5 x 10(-9) to 1.0 x 10(-9) M. The increased antiproliferative effect of everolimus by fluvastatin was prevented in the presence of mevalonate, farnesol, or geranylgeraniol, suggesting the involvement of prenylated proteins. Cell cycle analysis and [3H]thymidine incorporation assay demonstrated that the two drugs synergistically interfered with the progression of G(1) phase. In particular, the drug combination significantly up-regulated p27(Kip1) levels by 47.0%, suppressed cyclin E by 43.0%, and it reduced retinoblastoma (Rb) hyperphosphorylation by 79.0%, compared with everolimus alone. Retroviral overexpression of cyclin E conferred a significant resistance of rat SMCs to the antiproliferative action of the drug combination, measured by cell counting, [3H]thymidine incorporation, and cell cycle analysis, with higher levels of hyperphosphorylated form of Rb. Taken together, these results demonstrated that everolimus acts synergistically with fluvastatin to inhibit SMC proliferation by altering the expression of cyclin E and p27(kip1), which affects Rb phosphorylation and leads to G(1) phase arres

35 años de análisis de isótopos estables en la arqueología Argentina: conceptos, fundamentos, metodología y aplicaciones

El objetivo de este trabajo es celebrar más de tres décadas de la integración de los análisis de isótopos estables en investigaciones arqueológicas en nuestro país. Se presenta una síntesis sobre los conceptos,fundamentos teóricos y metodológicos y las aplicaciones, principalmente en tres grandes temas: paleodieta, paleomovilidad y paleoambiente. A su vez, brindamos ejemplos de abordajes isotópicos sobre problemáticas de paleodietas en sociedades cazadoras recolectoras y agricultoras; movilidad de grupos humanos; estrategias de pastoreo; preparación y cocción de alimentos; estudios paleoambientales y paleoclimáticos. Este compendio puede resultar una referencia útil para estudiantes e investigadores que decidan adentrarse en este campo de investigación. Los casos mencionados no agotan el estado de la cuestión, ni abarcan todas las regiones donde fueron desarrollados estos estudios, sino que el propósito es mostrar la diversidad temática y el modo en que los isótopos estables permiten ampliar el conocimiento sobre las sociedades en el pasado.The main goal of this work is to celebrate more than three decades of the application of stable isotope analyses in Argentinian archaeology. We present a synthesis of the concepts, theoretical and methodological aspects and applications covering three main topics: paleodiet, paleomobility and paleoenvironment. At the same time, we provide examples of isotopic approaches to study problems such as paleodiets in hunter-gatherer and agricultural societies, human mobility, herding strategies, food preparation and cooking, and paleoenvironmental and paleoclimatic studies. This compendium will be a useful reference for students and researchers inclined to enter this field of research. However, the cases mentioned here do not represent the state of art nor do they cover all the Argentinian regions where these studies were carried out, but rather show the thematic diversity and the way in which stable isotope analyses allow to broaden our knowledge about societies in the past.Introducción - Conceptos básicos, fundamentación y notación de los análisis de isótopos estables - Espectrometría de masas - Relaciones isotópicas mayormente utilizadas en arqueología -- Isótopos estables del carbono -- Isótopos estables del nitrógeno -- Isótopos estables del oxígeno e hidrógeno -- Otras relaciones isotópicas de interés: azufre y estroncio - Tejidos y materiales -- Tejidos biológicos -- Residuos orgánicos -- Carbonatos biogénicos -- Sedimentos - Conservación, contaminación y diagénesis -- Fracción orgánica o colágeno -- Fracción Mineral o Bioapatita - Discriminación y fraccionamiento isotópico - Interpretación paleodietaria y ecología isotópica - Abordajes isotópicos de problemáticas en arqueología argentina - Consideraciones finales y perspectivas futura

Pharmacological screening using an FXN-EGFP cellular genomic reporter assay for the therapy of Friedreich ataxia

Copyright @ 2013 Li et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.Friedreich ataxia (FRDA) is an autosomal recessive disorder characterized by neurodegeneration and cardiomyopathy. The presence of a GAA trinucleotide repeat expansion in the first intron of the FXN gene results in the inhibition of gene expression and an insufficiency of the mitochondrial protein frataxin. There is a correlation between expansion length, the amount of residual frataxin and the severity of disease. As the coding sequence is unaltered, pharmacological up-regulation of FXN expression may restore frataxin to therapeutic levels. To facilitate screening of compounds that modulate FXN expression in a physiologically relevant manner, we established a cellular genomic reporter assay consisting of a stable human cell line containing an FXN-EGFP fusion construct, in which the EGFP gene is fused in-frame with the entire normal human FXN gene present on a BAC clone. The cell line was used to establish a fluorometric cellular assay for use in high throughput screening (HTS) procedures. A small chemical library containing FDA-approved compounds and natural extracts was screened and analyzed. Compound hits identified by HTS were further evaluated by flow cytometry in the cellular genomic reporter assay. The effects on FXN mRNA and frataxin protein levels were measured in lymphoblast and fibroblast cell lines derived from individuals with FRDA and in a humanized GAA repeat expansion mouse model of FRDA. Compounds that were established to increase FXN gene expression and frataxin levels included several anti-cancer agents, the iron-chelator deferiprone and the phytoalexin resveratrol.Muscular Dystrophy Association (USA), the National Health and Medical Research Council (Australia), the Friedreich’s Ataxia Research Alliance (USA), the Brockhoff Foundation (Australia), the Friedreich Ataxia Research Association (Australasia), Seek A Miracle (USA) and the Victorian Government’s Operational Infrastructure Support Program

Resveratrol Inhibits Protein Translation in Hepatic Cells

Resveratrol is a plant-derived polyphenol that extends lifespan and healthspan in model organism. Despite extensive investigation, the biological processes mediating resveratrol's effects have yet to be elucidated. Because repression of translation shares many of resveratrol's beneficial effects, we hypothesized that resveratrol was a modulator of protein synthesis. We studied the effect of the drug on the H4-II-E rat hepatoma cell line. Initial studies showed that resveratrol inhibited global protein synthesis. Given the role of the mammalian Target of Rapamycin (mTOR) in regulating protein synthesis, we examined the effect of resveratrol on mTOR signaling. Resveratrol inhibited mTOR self-phosphorylation and the phosphorylation of mTOR targets S6K1 and eIF4E-BP1. It attenuated the formation of the translation initiation complex eIF4F and increased the phosphorylation of eIF2α. The latter event, also a mechanism for translation inhibition, was not recapitulated by mTOR inhibitors. The effects on mTOR signaling were independent of effects on AMP-activated kinase or AKT. We conclude that resveratrol is an inhibitor of global protein synthesis, and that this effect is mediated through modulation of mTOR-dependent and independent signaling

How do cardiologists select patients for dual antiplatelet therapy continuation beyond 1 year after a myocardial infarction? Insights from the EYESHOT Post-MI Study

Background: Current guidelines suggest to consider dual antiplatelet therapy (DAPT) continuation for longer than 12 months in selected patients with myocardial infarction (MI). Hypothesis: We sought to assess the criteria used by cardiologists in daily practice to select patients with a history of MI eligible for DAPT continuation beyond 1 year. Methods: We analyzed data from the EYESHOT Post-MI, a prospective, observational, nationwide study aimed to evaluate the management of patients presenting to cardiologists 1 to 3 years from the last MI event. Results: Out of the 1633 post-MI patients enrolled in the study between March and December 2017, 557 (34.1%) were on DAPT at the time of enrolment, and 450 (27.6%) were prescribed DAPT after cardiologist assessment. At multivariate analyses, a percutaneous coronary intervention (PCI) with multiple stents and the presence of peripheral artery disease (PAD) resulted as independent predictors of DAPT continuation, while atrial fibrillation was the only independent predictor of DAPT interruption for patients both at the second and the third year from MI at enrolment and the time of discharge/end of the visit. Conclusions: Risk scores recommended by current guidelines for guiding decisions on DAPT duration are underused and misused in clinical practice. A PCI with multiple stents and a history of PAD resulted as the clinical variables more frequently associated with DAPT continuation beyond 1 year from the index MI